Chiron Corporation

Cetus Corporation

Leland Stanford Junior University

Berlex Laboratories, Inc.

Nuvelo, Inc.

Hoffmann-la Roche Inc.

Novartis Vaccines & Diagnostics, Gmbh

Michael A Innis

Abla A Creasey

Ronald N Zuckermann

Christoph Reinhard

Fred Ehrenkranz Cohen

Francis P McCormick

Tetsuo Uno

John E Murphy

Nathalie Dubois-Stringfellow

Varavani J Dwarki

Gordon M Ringold

Radoje Drmanac

David H Gelfand

Lewis T Williams

Giulia C Kennedy

Snezana Drmanac

Klaus Giese

David B Kita

Jaime A Escobedo

Filippo M Randazzo

David Pot

Pablo Dominguez Garcia

Ivan Labat

George Lamson

Altaf Kassam

Julie Sudduth-Klinger

Birgit Stache-Crain

Isabel Zaror

Radomir Crkvenjakov

Mark Dickson

Dena Leshkowitz

Veronica Garcia

Lee William Jones

Elizabeth M Scott

Kirston E Koths

Robert F Halenbeck

Alice M Wang

Ze'ev Shaked

Jack H Nunberg

Kenneth Crawford

James H Meade

Robert J Bishop

Kenneth B Myambo

Mary Ann Brow

Jeffrey E Flatgaard

This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.

Compositions and methods for polynucleotide delivery

This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostic and therapeutic agents employing such novel human polynucleotides, their corresponding genes or gene products, e.g., these genes and proteins, including probes, antisense constructs, and antibodies.

Human genes and gene expression products V

Human genes and gene expression products II

Chimeric oligonucleotide of the formula 5'-W&#x2014;X&#x2014;Y&#x2014;X&#x2014;Z-3&#x2032;, where W represents a 5&#x2032;-O-alkyl nucleotide, each of Xand Xrepresents a block of seven to twelve phosphodiester-linked 2&#x2032;-O-alkyl ribonucleotides, Y represents a block of five to twelve phosphorothioate-linked deoxyribonucleotides, and Z represents a blocking group effective to block nuclease activity at the 3&#x2032; end of the oligonucleotide, are described. These compounds exhibit high resistance to endo- and exonucleases, high sequence specificity, and the ability to activate RNAse H, as evidenced by efficient and long-lasting suppression of target mRNA. The oligonucleotides are preferably transfected into cells in formulations containing a lipid-peptoid conjugate carrier molecule of the formulaL-linker-[N(CHCHNH)CH(C&#x2550;O)&#x2014;N(CHCHR)CH(C&#x2550;O)&#x2014;N(CHCHR)CH(C&#x2550;O)]&#x2014;NH,where L is a lipid moiety, including a steroid, and each group R is independently selected from alkyl, aminoalkyl, and aralkyl.

Chimeric antisense oligonucleotides and cell transfecting formulations thereof

Chimeric proteins possessing Kunitz-type domain 1 of TFPI-2 and Kunitz-type domain 2 of TFPI are disclosed, as are muteins of TFPI and TFPI-2. Nucleic acid sequences, expression vectors and transformed host cells encoding and capable of producing the disclosed chimeric proteins and muteins are also disclosed. Finally, methods for prevention and treatment of septic shock using the chimeric proteins and muteins are disclosed.

Chimeric proteins

Expression vectors and transfection systems providing high expression of a desired polypeptide are provided. Also provided are methods of using the expression vectors and transfection systems and mammalian cells modified by these compositions and methods.

Expression vectors, transfection systems, and method of use thereof

Polycationic polymers

Pichia secretory leader for protein expression

A method for the production of Tissue Factor Pathway Inhibitor (TFPI) and Tissue Factor Pathway Inhibitor 2 (TFPI-2), and muteins thereof is disclosed wherein the protein is retained within a yeast cell during growth of the yeast cell and recovered from an insoluble fraction prepared from yeast cells containing the protein.

Production of tissue factor pathway inhibitor

Chimeric proteins containing sequences from MCP and DAF and further containing peptide sequences capable of binding glycosaminoglycans. Nucleotide sequences encoding the chimeric proteins, expression vectors containing the nucleotide sequences, as well as transformed host cells capable of producing the chimeric proteins are claimed.

Chimeric MCP and DAF proteins with cell surface localizing domain

.beta.-interferon is produced in Chinese hamster ovary cells (CHO) in high amounts.

Human interferon-.beta. (IFN-.beta.) produced in Chinese hamster ovary

Growing community of inventors

Moraga, CA, United States of America

Michael A Innis